Endpoints News 3. März 2026 After years of dispute with FDA, Vanda will get a public hearing for jet lag drug
Endpoints News 3. März 2026 FDA explains how some copycat drugs can still win three years of exclusivity
Endpoints News 3. März 2026 EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
Endpoints News 3. März 2026 Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work
Endpoints News 3. März 2026 Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market
Endpoints News 2. März 2026 United Therapeutics to take pulmonary hypertension drug to FDA for approval
Endpoints News 2. März 2026 Aardvark's stock plummets on study pause; BioNTech heads to Phase 3 with DualityBio ADC
Endpoints News 2. März 2026 Roche gets third pivotal win with MS drug, but liver signal could be a problem